Trials / Recruiting
RecruitingNCT07108309
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
A Randomized, Open-label, Comparative Clinical Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- Sponsor
- Biocad · Industry
- Sex
- Female
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCD-236 | as an intravenous infusion |
| DRUG | Chemotherapy | CHT (at the investigator's discretion): |
Timeline
- Start date
- 2024-07-15
- Primary completion
- 2025-12-01
- Completion
- 2027-05-01
- First posted
- 2025-08-07
- Last updated
- 2025-08-07
Locations
47 sites across 2 countries: Belarus, Russia
Source: ClinicalTrials.gov record NCT07108309. Inclusion in this directory is not an endorsement.